Biotech companies at FoG London 2027
Jan 27–28, 2027 London, UK ~8.3k attendees Website
11 biotech companies are at FoG London 2027 — 12 presentations on the program. Most represented: Relation Therapeutics (5 on the program), Astex Pharmaceuticals (1 on the program), Axovia Therapeutics (1 on the program). 1 of them have their own page in this guide. As of Oct 29, 2026.
Topic
Top represented
Showing 1–11 of 11 organizations
| Organization | FoG London 2027 Attendance |
|---|---|
Relation Therapeutics London, UK | |
Drug discovery company combining single-cell and functional genomics data from patient tissue with machine learning to find drug targets. | Talk Wed Jan 27 11:30–12:00 Relation's AI & Deep Learning Platform: What datasets the ML models are trained on What biological and genomic datasets train deep learning models for drug discovery, and how data quality and diversity shape their performance. Talk Wed Jan 27 12:30–13:00 Spatial Total RNA Profiling via in situ Polyadenylation How a new method maps all of each cell's RNA in tissue, revealing splicing and non-coding RNA even in wax-preserved clinical samples. Panel Wed Jan 27 17:30–18:00 Choosing the Right Sequencing Technology: Short Reads, Long Reads & Beyond How researchers weigh short-read and long-read sequencing on accuracy, resolution, throughput and cost, and when to combine them. Also |
Astex Pharmaceuticals Cambridge, UK | |
Drug discovery and development company, part of Otsuka, known for fragment-based small-molecule medicines in oncology. | Panel Thu Jan 28 11:30–12:00 Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error? Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured. |
Axovia Therapeutics London, UK | |
Develops AAV gene therapies for ciliopathies, starting with BBS1-linked Bardet-Biedl syndrome, aiming to prevent blindness and treat genetic obesity. | Panel Wed Jan 27 17:30–18:00 How Can We Bridge the Gap from Discovery to GMP Manufacturing? When and how cell and gene therapy developers should plan manufacturing and regulation so a lab process can scale without losing quality. |
DP DISCO Pharmaceuticals Cologne, Germany | |
Drug discovery company mapping cancer cell-surface proteins to find targets for antibody-based and other targeted therapies. | Panel Wed Jan 27 17:30–18:00 Using High Dimensional Multi-Omic Data in Drug Discovery & Translational Research How combining several layers of molecular data can reveal drug targets and biomarkers, and what slows their path to the clinic. |
EB Entelo Bio Oxford, UK | |
University of Oxford spinout using isoform-aware machine learning and multi-omics to discover drug targets, focused on movement and ageing disorders. | Panel Thu Jan 28 11:30–12:00 Are We Seeing Real Breakthroughs from AI, or Just Faster Trial and Error? Whether AI-discovered drugs now reaching mid-stage trials are truly better molecules, and how success for AI in drug discovery should be measured. |
Immunocore Abingdon, UK | |
Develops T cell receptor-based bispecific immunotherapies for cancer, infectious and autoimmune diseases, including the first approved TCR therapy. | Talk Wed Jan 27 15:30–16:00 Engineering the Next Generation of Immunotherapies: Lessons from the First Approved T Cell Receptor-Based Therapy Lessons from building the first approved T cell receptor-based therapy, and how its platform is now being extended to new molecules. |
Lir Therapeutics London, UK | |
Company using an AI design engine to engineer AAV gene therapy vectors with better tissue targeting and lower doses. | Panel Wed Jan 27 12:30–13:00 Designing the Next Generation of Rare Disease Therapies: From Advanced Genomics to AI-Enabled Therapeutic Innovation How better knowledge of disease genetics and AI could shape the design of more precise, personalised treatments for rare diseases. |
MeiraGTx New York, NY | |
Clinical-stage genetic medicine company developing gene therapies and riboswitch gene-regulation technology, with manufacturing in London. | Panel Wed Jan 27 12:30–13:00 Designing the Next Generation of Rare Disease Therapies: From Advanced Genomics to AI-Enabled Therapeutic Innovation How better knowledge of disease genetics and AI could shape the design of more precise, personalised treatments for rare diseases. |
Flagship Pioneering company studying somatic mutations in healthy and diseased tissue to discover drug targets. | Talk Thu Jan 28 12:30–13:00 Drug Target Discovery through Somatic Genomics How somatic mutations, changes acquired in body cells, reveal disease-driving and protective biology that can point to new drug targets. |
Resolution Therapeutics London, UK | |
Clinical-stage company developing engineered macrophage cell therapies to repair organ damage, starting with liver cirrhosis. | Panel Wed Jan 27 17:30–18:00 How Can We Bridge the Gap from Discovery to GMP Manufacturing? When and how cell and gene therapy developers should plan manufacturing and regulation so a lab process can scale without losing quality. |
Engitix Therapeutics London, UK | |
Drug discovery company using human extracellular matrix models to find treatments for fibrosis, inflammation and solid tumours. | Also |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse FoG London 2027 by
Organization type
Topic
- Genomic medicine & rare disease 54
- Cancer genomics & diagnostics 31
- AI in drug discovery & diagnostics 43
- Biodata & bioinformatics 33
- Single-cell genomics 24
- Spatial biology 19
- Multi-omics & proteomics 31
- Epigenetics & translational omics 16
- Pharmacogenomics & patient stratification 16
- Women’s and children’s health 13
- Cell & gene therapy 18
- Microbiome & pathogen genomics 17
- Plant & agricultural genomics 13
- Population & social genomics 23
Exhibit hall
Everyone
Not affiliated with or endorsed by Front Line Genomics or the Festival of Genomics. Submit a correction